Global Cancer Therapeutics and Supportive Care Drugs Market Size By Type (Cancer Therapeutics, Supportive Care Drugs), By Application (Hospital, Retail), By Region, And Segment Forecasts, 2023 to 2032

The Global Cancer Therapeutics and Supportive Care Drugs Market was valued at USD 156.4 billion in 2023 and is projected to reach USD 268.3 billion by 2031, growing at a CAGR of 6.9% during the forecast period from 2023 to 2031. This growth is fueled by rising global cancer prevalence, the launch of novel biologics and targeted therapies, and growing investment in oncology R&D. The market encompasses a broad range of products, including chemotherapy, targeted therapy, immunotherapy, hormone therapy, and supportive care agents like antiemetics and growth factors. Increasing healthcare access in emerging markets and ongoing advances in precision medicine are significantly enhancing treatment outcomes and expanding the market landscape.

Drivers

1. Rising Global Cancer Burden:

With cancer now the second leading cause of death worldwide, the need for effective therapeutics is critical. Aging populations and lifestyle factors are increasing the incidence of cancers such as breast, lung, colorectal, and prostate, thereby driving market growth.

2. Advancements in Oncology Drug Development:

The emergence of personalized medicine, immunotherapies (e.g., checkpoint inhibitors), and next-generation sequencing (NGS) is revolutionizing cancer treatment, allowing for targeted and more effective therapies with fewer side effects.

3. Increased Healthcare Spending and Access:

Improved healthcare infrastructure and reimbursement systems in developing economies are enabling greater access to advanced cancer treatments, boosting global demand.

Restraints

1. High Cost of Treatment:

Cancer therapeutics, particularly biologics and immunotherapies, are among the most expensive drugs. High costs limit access in low-income countries and strain public and private healthcare systems.

2. Adverse Effects and Resistance Issues:

Many cancer therapies cause severe side effects and may become less effective over time due to resistance mechanisms, creating challenges in long-term disease management.

Opportunity

1. Emerging Markets and Biosimilars:

As countries in Asia-Pacific and Latin America scale up their oncology care capabilities, they represent a high-growth frontier. Additionally, the entry of biosimilars is expected to reduce costs and expand patient access.

2. Expansion of Supportive Care Segment:

Demand for drugs that manage side effects of cancer treatments—such as anti-nausea agents, analgesics, and bone marrow stimulants—is increasing as survival rates improve and patients require long-term management.

Market by System Type Insights

The Targeted Therapy segment held the largest market share in 2023. This segment includes monoclonal antibodies and small molecule inhibitors, which are widely adopted due to their ability to specifically attack cancer cells while sparing healthy tissue. Immunotherapy, particularly checkpoint inhibitors and CAR-T cell therapies, is expected to register the highest CAGR due to its potential to provide durable remission and its application across multiple cancer types.

Market by End-use Insights

Hospitals and Cancer Treatment Centers accounted for the majority of the revenue in 2023. These settings are primary hubs for complex oncology treatments that require sophisticated equipment and healthcare personnel. However, the Homecare segment is projected to grow rapidly, driven by the increasing use of oral oncolytics and supportive care drugs that enable outpatient or at-home treatment.

Market by Regional Insights

North America led the global cancer therapeutics and supportive care drugs market in 2023, accounting for over 40% of the revenue. This dominance is attributed to robust healthcare infrastructure, high awareness, early diagnosis, and access to advanced therapeutics. Asia-Pacific is forecasted to be the fastest-growing region, with China and India at the forefront due to increasing cancer cases, growing investments in healthcare, and adoption of novel therapies.

Competitive Scenario

Leading players in the market include Roche Holding AG, Bristol Myers Squibb, Novartis AG, Merck & Co., Inc., Johnson & Johnson, AstraZeneca, Pfizer Inc., Amgen Inc., Eli Lilly and Company, and Gilead Sciences, Inc. These companies are focusing on clinical trials, regulatory approvals, strategic collaborations, and the expansion of their oncology portfolios.

Scope of Work – Global Cancer Therapeutics and Supportive Care Drugs Market

Key Market Developments

2023: Roche’s new immunotherapy combination approved for NSCLC patients in the U.S., offering improved survival rates.

2024: Merck & Co. expanded its KEYTRUDA franchise with approvals for additional cancer types, including cervical and gastric cancers.

2025: AstraZeneca launched a novel antibody-drug conjugate (ADC) therapy for HER2-low breast cancer patients in global markets.

FAQs

1. What is the current market size of the Global Cancer Therapeutics and Supportive Care Drugs Market?

The market was valued at USD 156.4 billion in 2023.

2. What is the major growth driver of the Global Cancer Therapeutics and Supportive Care Drugs Market?

The major driver is the rising global burden of cancer and continuous innovations in targeted and immunotherapies.

3. Which is the largest region during the forecast period in the Global Cancer Therapeutics and Supportive Care Drugs Market?

North America is the largest region, driven by advanced healthcare systems and high therapeutic adoption rates.

4. Which segment accounted for the largest market share in Global Cancer Therapeutics and Supportive Care Drugs Market?

The Targeted Therapy segment accounted for the largest market share in 2023.

5. Who are the key market players in the Global Cancer Therapeutics and Supportive Care Drugs Market?

Key players include Roche Holding AG, Bristol Myers Squibb, Novartis AG, Merck & Co., AstraZeneca, Pfizer Inc., and Amgen Inc.